Anthony Dubroc
Co-founder · CEO
Sleep · Mental health
Digital therapeutics for sleep and mental health
Di&Care is a French company dedicated to the development and commercialization of ‘digital therapeutics’ in the field of sleep and mental health. Our treatments are based on the gold standard therapies in the management of these conditions.
The Noxxea prescription platform is for healthcare professionals.
Insomnia in numbers
70 %
of insomnia sufferers experience a lack of energy during the day
56 %
of French people reported experiencing sleep disturbances in the past 12 months
39 %
of insomniacs hesitate to talk to a healthcare professional about their sleep troubles
50 %
would be willing to use an application prescribed by their doctor to improve their sleep
Our approach
An innovative project for the benefit of patients
Our treatment is based on the European gold standard therapy for managing chronic insomnia: Cognitive Behavioral Therapy (CBT). Noxxea© will be the only solution to integrate Cognitive Behavioral Therapy (CBT), as well as digital phenotyping, which will allow for optimized individualization of the treatment.
Cognitive Behavioral Therapy (CBT) is the gold standard treatment for many other psychiatric conditions such as anxiety disorders, phobic disorders, and depression. Once again, digital phenotyping will optimize treatment individualization with the goal of more effectively treating these patients.
Noxxea
The Noxxea© project aims to develop a Digital Cognitive Behavioral Therapy accessible to everyone.
About
Who are we?
Di&Care was founded by two pharmacists holding a University Diploma in ‘Sleep and its Pathology.’ With 15 years of management experience in the healthcare industries, our ambition is to develop innovative digital solutions in the field of mental health.
This project is supported by BPI and an anchorage in the Hauts-de-France within the Eurasanté incubator in Lille ensures a vision oriented towards Europe.
Charles de la Personne
Co-founder · CSO
Fabien Bousquet
CTO
Supported by
News
Latest news
April 2026
Noxxea in « Challenges »
Di&Care featured in Challenges! A great recognition of our commitment to improving insomnia care with NOXXEA. We are proud to see Di&Care listed in Challenges magazine among the 100 startups to invest in.
Read more →
Clinical study
Results of the REST-NOXXEA study
Impact of an innovative first-line digital therapy in severe to moderate chronic insomnia (insomnia disorder).